Feike Sijbesma, Chairman of EuropaBio, the European Biotechnology industry association announced that Mr. Jack Huttner (1), Dr Bernward Garthoff (2), Mr Tom Saylor (3) and Mr. Odd Magne Rødseth (4) have been appointed to the EuropaBio main Board. 

Jack Huttner is Vice President of Corporate Communications and Public Affairs, Genencor International, Inc and Dr Bernward Garthoff is Member of the Board of Management of Bayer CropScience AG.

Tom Saylor is Chief Executive, Arecor. and represents the BIA, the UK BioIndustry Association on the EuropaBio board while Odd Magne Rødseth is CEO Aqua Gen AS and Chairman of the Norwegian Biotechnology Association.

These appointments bring elected Board members of EuropaBio to a total of twenty-one (5) representing large and small biotech companies based throughout Europe. Speaking on the appointments Feike Sijbesma said "These board members representing the full range of biotech sectors as well as large and small companies alike will strengthen EuropaBio's capacity to contribute to the European policy agenda on biotechnology and life sciences."

EuropaBio, the European Association for Bioindustries, has 35 corporate members operating worldwide and 24 national biotechnology associations representing some 1500 small and medium sized enterprises involved in research and development, testing, manufacturing and distribution of biotechnology products.

Newly elected Board Members - Profiles

(1)  Mr. Jack Huttner, Vice President of Corporate Communications and Public Affairs, Genencor International, Inc

Jack Huttner has global responsibility for corporate communications, government, trade and public relations for Genencor International - one of the largest biotechnology companies in the world with the European headquarters in Leiden, the Netherlands.  The company operates three manufacturing plants in Europe:  two in Finland and one in Belgium.

Huttner was the founding Executive Director of the New York Biotechnology Association, Inc., (NYBA) founder of the New York State Biotech association and has served on a number of boards and commissions including those of the New York Academies of Medicine and Science and the Councils for Biotechnology at Stony Brook and Cornell Universities. Currently, Huttner serves on the Biomass Technical Advisory Committee formed by an Act of the U.S. Congress to oversee the federal government's $250 million bio-energy R&D budget.  He is chairman of the Industrial and Environmental governing board of the Biotechnology Industry Organization (BIO) in Washington, DC and has been active in EuropaBio for several years.  He also represents industry at an OECD advisory committee for biotechnology and sustainable development.  
 
Genencor is a diversified biotechnology company focussing on two markets: bioproducts and health care. For the bioproducts market, Genencor discovers, develops, and sells biocatalysts and other biochemicals for the industrial, consumer, and agri-processing markets. For the health care market, Genencor has drug development platforms in targeted biotherapeutics for cancer.

(2) Dr. Bernward Garthoff, Member of the Board of Management of Bayer Crop Science AG

Dr. Bernward Garthoff is a member of the Board of Management and responsible for Technology at the Bayer CropScience AG.

Bernward Garthoff studied veterinary medicine at Hannover University and joined Bayer in 1976 where he held a variety of functions in pharmacological research. Returning to Germany, after a period in the US as Senior Vice President for Research and Development at Bayer's then U.S. pharmaceuticals subsidiary, Miles, Dr Garthoff become Head of the Institute for Cardiovascular and Arteriosclerosis Research.

He moved to the Crop Protection Business Group in 1994, becoming Head of Portfolio Management in April of that year. He has recently managed the integration process entrained by the acquisition of Aventis CropScience.

Bayer CropScience AG is one of the world's leading companies in the areas of crop protection, seeds and biotechnology.

(3) Mr.  Tom Saylor, CEO, Arecor Ltd and representative of the UK BioIndustry Association

Tom Saylor is CEO of Arecor Limited, a company focused upon advanced drug delivery systems for parenterals. Tom has extensive experience in building and managing entrepreneurial organizations and negotiating commercial agreements. Previously, he was CEO of Sirus, a drug targeting and delivery company based in Cambridge, England. Prior to joining Sirus, Tom was Chairman and founder of Lotus Healthcare Corporation, an Asian-based integrated pharmaceutical company. Tom built Lotus Healthcare from a small marketing group into a leading producer and marketer of analgesics, cardiovascular and GI products with two GMP manufacturing sites and a sales staff of 100 representatives covering the top 35 cities of China. Tom was also Chief Executive Officer of Cell Systems Limited, a company focusing on medical applications of cryopreservation and algal biotechnology. Previously, Tom was Executive Vice President of a multi-billion dollar diversified industrial and financial group based in New York and a prinicipal negotiator in the Tokyo Round of multilateral trade negotiations.

Arecor is an emerging European speciality pharmaceutical business focussing on a range of improved hospital injectibles.  Arecor is seeking to improve the safety, efficacy and convenience of injectibles through new presentations and advanced formulations without adding to the cost burden. The Company is developing a range of value added products as conventional vial or ampoule presentation or pre-filled syringes for CNS, critical care, and oncology adjunctive therapies. These differentiated products will respond to an increasing demand for 'patient-ready' medicines and growing concerns over needlestick injuries and dosing errors. The Company is also building proprietary advantages through its patented drug delivery and formulation technologies providing for a new generation of value-added and performance enhanced injectibles. 

(4) Mr. Odd Magne Rødseth, CEO, Aqua Gen AS and Chairman of the Norwegian Bioindustry Association
Odd Magne Rødseth is CEO of Aqua Gen AS - which is Norway's premier producer of eyed ova from Atlantic salmon and rainbow trout. Mr. Rødseth has a Master's Degree in Microbiology from the University of Bergen. He is a former researcher at the University of Bergen and the Institute of Marine Research (IMR) where his main research topics where fish immunology and developing vaccines for the aquaculture industry where he was part of the "Frisk Fisk" programme that was at the basis of the first vaccine against cold water vibriosis. For the last ten years he has been Research Director of the Dutch pharmaceutical company Intervet International in charge of developing new fish vaccines.

Aqua Gen AS is Norway's premier producer of eyed ova from Atlantic salmon and rainbow trout.  

(5) EuropaBio Board of Management

CHAIRMAN                               
Mr. Feike SIJBESMA
Member of the Managing Board
DSM

VICE CHAIRMAN
(Agri-Food Board)                      
(Finance and Treasury)
Dr. Hans KAST
President & CEO
BASF Plant Science Holding GmbH

VICE CHAIRMAN                  
(Health Care Board)            
Dr. Erik TAMBUYZER
Vice President, Genzyme Europe

VICE CHAIRMAN                   
(Emerging Enterprises Board)
Dr. Philippe POULETTY
CEO, Truffle Ventures
Chairman, France Biotech (France)

VICE CHAIRMAN                   
(Industrial Biotechnology Board) 
Mr. Steen RIISGAARD
President and CEO, Novozymes A/S

MEMBERS

Dr. Philippe ARCHINARD
Chief Executive Officer, Innogenetics N.V.     

Mr. Georg KRESSE
Head Pharma Research, F. Hoffmann La Roche (Switzerland)
       
Mr. Philippe CASTAING
General Manager Europe-Africa
Monsanto Services International S.A.

Dr. Bernward GARTHOFF
Member of the Board of Management
Bayer CropScience (Germany)
       
Dr. Sergio DOMPE
Managing Director, Dompé Biotec
President, Assobiotec (Italy)

Dr. Odd Magne RØDSETH
Chairman, NBA (Norway) 

Dr. Hans DONS
CEO, Keygene
Vice-Chairman, Niaba (The Netherlands)

Dr. Romeo PAIONI
Member of the Corporate Executive Group
Head of Scientific and External Affairs
Novartis Pharma AG
       
Mr. André GOIG
Regional Head -Syngenta Seeds Europe & MEA.
Syngenta International AG      

Dr. Andrea RAPPAGLIOSI
Vice President, Health Policy & Governmental. Relations, Serono
       
Dr. Peter GOODFELLOW
Senior Vice President, Discovery Research
GlaxoSmithKline

Mr. Jack HUTTNER
Vice President Communications and Public Affairs
Genencor International Inc
       
Dr. Harry JONGENEELEN
Senior Vice President External Affairs Foods
Unilever N.V.  

Dr. Tom SAYLOR
Chief Executive, BIA (United Kingdom)  

Mr. Mathieu VRIJSEN
President, Europe, Middle East & Africa
DuPont de Nemours International

Dr. Peter STADLER
Managing Director, Artemis
DIB, (Germany) 

EX-OFFICIO
Dr. Johan VANHEMELRIJCK
Secretary General, EuropaBio